Company intelligence / Profile preview

IconOVir Bio

New York, New York, United Statesiconovir.com ↗

Ownership: Private
Employees: ~50
Development stage: Other

Overview

IconOVir began a Phase 1 trial in July 2023 for its lead candidate ICVB-1042, but recently stopped enrolling patients. In February 2025, the company sold ICVB-1042 to UroGen Pharma for $4 million in stock plus potential future milestone payments and royalties[6].

Therapeutic areas: Oncology
Modalities: Oncolytic virus therapy
Industry: Biotech

Drug pipeline

1 asset

ICVB-1042

Partnerships

UroGen Pharma (sold ICVB-1042 to them in February 2025)

Beyond the preview

Go deeper on IconOVir Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IconOVir Bio.